Press Release

Stockholm November 12, 2019

Updated timetable for submission of the application to the European Medicines Agency

Intervacc will shortly apply to the European Medicines Agency (EMA) to submit the company's registration application for Strangvac's approval during the first quarter of 2020.

The company has today decided to enter into a dialogue with EMA about submitting the registration application, provisionally at the end of February. Until then the company will strengthen the application and ensure that all the guidance of our expert advisor and the advisory meetings with EMA are met. This will pave the way for a rapid and straightforward approval process.

"When submitting to EMA, we will have a robust application" says Andreas Andersson, CEO of Intervacc and continues *"to enter into dialogue with EMA to determine the submission schedule is a milestone in the company's development"*.

For more information please contact:

Andreas Andersson, CEO
Phone: +46 (0)8 120 10 601
Cell: +46 (0)73 335 99 70
E-mail: andreas.andersson@intervacc.com

The information was submitted for publication, through the agency of the contact person set out above on November 12, 2019 15.35 CET.

About Intervacc
Intervacc AB (publ) is a company within the Biotechnology sector. The Company´s main area is to develop modern sub-unit vaccines against economically important bacterial infections, within animal health. The company´s vaccine candidates are based on several years of research at Karolinska Institutet and Swedish University of Agricultural Research where the foundation was laid for the company´s research and development work. The Intervacc share has been listed on the NASDAQ First North Growth Market since April 2017 with Eminova Fondkommission AB, adviser@eminova.se, +46 (0)8–684 211 10 as Certified Adviser.

About Strangvac®
Strangvac®, a modern vaccine against Strangles, a highly contagious and serious infection in horses caused by the bacterium *Streptococcus equi*. Strangvac® consists of only soluble recombinant proteins, is injected intramuscularly and totally devoid of any living infectious agent. This results in a well-tolerated vaccine with excellent safety profile, as expected of a modern vaccine.

Contact information for Certified Adviser
Eminova Fondkommission AB
E-mail: adviser@eminova.se, Phone: +46 (0)8 – 684 211 10